We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
+5.11%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.64B
AUM Growth
+$64M
(+2.5%)
Cap. Flow
-$23.9M
Cap. Flow
% of AUM
-0.91%
Top 10 Holdings %
Top 10 Hldgs %
39.72%
Holding
198
New
11
Increased
45
Reduced
37
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$17.5M |
| 2 |
Stryker
SYK
|
+$12.2M |
| 3 |
AstraZeneca
AZN
|
+$12.1M |
| 4 |
Danaher
DHR
|
+$11.9M |
| 5 |
Pfizer
PFE
|
+$11.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sarepta Therapeutics
SRPT
|
+$13.6M |
| 2 |
SHPG
Shire pic
SHPG
|
+$12.8M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$12.3M |
| 4 |
Abbott
ABT
|
+$10.4M |
| 5 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$8.69M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.61% |
| 2 | Real Estate | 3% |
| 3 | Financials | 0.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Gilead Sciences
GILD
$163B
| $146M | 5.55% |
2,063,699
| – | – |
|
2
Amgen
AMGN
$209B
| $129M | 4.91% |
700,588
| – | – |
|
3
Biogen
BIIB
$30.7B
| $117M | 4.45% |
403,955
+25,252
| +7% | +$7.1M |
|
4
Johnson & Johnson
JNJ
$617B
| $108M | 4.11% |
893,082
| – | – |
|
|
5
UnitedHealth
UNH
$383B
| $104M | 3.96% |
425,317
+73,000
| +21% | +$17.5M |
|
|
CELG
6
DELISTED
Celgene Corp
CELG
| $99.4M | 3.77% |
1,251,470
-101,372
| -7% | -$8.42M |
|
7
Vertex Pharmaceuticals
VRTX
$122B
| $98.8M | 3.75% |
581,522
-32,562
| -5% | -$5.05M |
|
|
8
Pfizer
PFE
$142B
| $85.6M | 3.25% |
2,487,110
+324,362
| +15% | +$11.1M |
|
9
Illumina
ILMN
$31B
| $79.5M | 3.02% |
292,458
-10,691
| -4% | -$2.72M |
|
10
Merck
MRK
$321B
| $77.9M | 2.96% |
1,345,655
| – | – |
|
11
Viatris
VTRS
$20.7B
| $59.9M | 2.27% |
1,657,017
-69,950
| -4% | -$2.74M |
|
|
ALXN
12
DELISTED
Alexion Pharmaceuticals
ALXN
| $54.4M | 2.07% |
438,416
-60,559
| -12% | -$7.08M |
|
13
Regeneron Pharmaceuticals
REGN
$77.4B
| $50.5M | 1.91% |
146,237
+6,677
| +5% | +$2.09M |
|
14
AbbVie
ABBV
$455B
| $47.6M | 1.81% |
513,658
+62,920
| +14% | +$6.14M |
|
15
Incyte
INCY
$24.9B
| $43.2M | 1.64% |
645,442
| – | – |
|
|
AGN
16
DELISTED
Allergan plc
AGN
| $41.5M | 1.57% |
248,836
| – | – |
|
|
17
Abbott
ABT
$183B
| $38.2M | 1.45% |
627,019
-171,600
| -21% | -$10.4M |
|
18
Medtronic
MDT
$110B
| $36.3M | 1.38% |
423,693
-98,518
| -19% | -$8.23M |
|
19
Bristol-Myers Squibb
BMY
$132B
| $36M | 1.37% |
651,030
+125,308
| +24% | +$6.77M |
|
20
Eli Lilly
LLY
$1.03T
| $33.3M | 1.26% |
390,108
-96,757
| -20% | -$7.95M |
|
21
Thermo Fisher Scientific
TMO
$214B
| $31.6M | 1.2% |
152,695
+4,840
| +3% | +$1.03M |
|
22
Humana
HUM
$44B
| $31.3M | 1.19% |
105,053
-13,680
| -12% | -$4.01M |
|
|
23
Sarepta Therapeutics
SRPT
$1.64B
| $31M | 1.18% |
234,489
-144,027
| -38% | -$13.6M |
|
24
Idexx Laboratories
IDXX
$44.1B
| $28.2M | 1.07% |
129,608
-23,468
| -15% | -$4.84M |
|
|
25
AstraZeneca
AZN
$266B
| $27.3M | 1.04% |
389,444
+168,144
| +76% | +$12.1M |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q2 2018 Portfolio in Review
As of Q2 2018, Tekla Capital Management held 198 positions worth $2.64B, up 2.5% from $2.57B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Tekla Capital Management's Q2 2018 filing shows 11 new, 45 increased, 37 reduced and 18 closed positions. Its largest new stake was Whitehawk Therapeutics: 51,000 shares worth $3.17M. The largest sale was Sarepta Therapeutics, an estimated $13.6M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Real Estate and Financials.
- Tekla Capital Management's largest Q2 2018 buy was Whitehawk Therapeutics: 51,000 shares worth $3.17M.
- Tekla Capital Management added most to UnitedHealth in Q2 2018, an estimated $17.5M increase.
- Tekla Capital Management's biggest Q2 2018 reduction was Sarepta Therapeutics, cutting an estimated $13.6M.
- Tekla Capital Management fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $8.69M.
- Tekla Capital Management's ten largest holdings make up 40% of its $2.64B portfolio in Q2 2018.
- Tekla Capital Management opened 11 new positions and closed 18 in Q2 2018.
- Tekla Capital Management's portfolio value rose 2.5% quarter-over-quarter to $2.64B.
Based on Tekla Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.